Pamela Robey is used to disappointing the scientists who send samples, anxious to know whether the mesenchymal stem cells (MSCs) they have extracted from fat can be coaxed to turn into either bone or cartilage.
To Robey, that disappointment reflects a misunderstanding about what MSCs are and what they can do. MSCs have been proposed as treatments for a wide range of ailments including heart and brain injury, joint damage, Crohn’s disease and multiple sclerosis. But some scientists say that these clinical aspirations have far outrun the basic science.
An international group of scientists, industry experts and governmental organizations is trying to introduce scientific clarity to the field and keep expectations in check.
Read the full article here: Stricter standards sought to curb stem-cell confusion